KR20220113411A - KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 - Google Patents

KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 Download PDF

Info

Publication number
KR20220113411A
KR20220113411A KR1020227021509A KR20227021509A KR20220113411A KR 20220113411 A KR20220113411 A KR 20220113411A KR 1020227021509 A KR1020227021509 A KR 1020227021509A KR 20227021509 A KR20227021509 A KR 20227021509A KR 20220113411 A KR20220113411 A KR 20220113411A
Authority
KR
South Korea
Prior art keywords
pain
compound
human
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227021509A
Other languages
English (en)
Korean (ko)
Inventor
주니어 제임스 필립 존슨
그레고리 엔. 비치
Original Assignee
제논 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제논 파마슈티칼스 인크. filed Critical 제논 파마슈티칼스 인크.
Publication of KR20220113411A publication Critical patent/KR20220113411A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Guides In General And Applications Therefor (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
KR1020227021509A 2019-12-06 2020-12-04 KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 Pending KR20220113411A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US62/945,093 2019-12-06
US201962948010P 2019-12-13 2019-12-13
US62/948,010 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
KR20220113411A true KR20220113411A (ko) 2022-08-12

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021509A Pending KR20220113411A (ko) 2019-12-06 2020-12-04 KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도

Country Status (14)

Country Link
EP (1) EP4069211A1 (https=)
JP (1) JP2023504166A (https=)
KR (1) KR20220113411A (https=)
CN (1) CN114786658A (https=)
AU (1) AU2020397173A1 (https=)
BR (1) BR112022010733A2 (https=)
CA (1) CA3159436A1 (https=)
CL (1) CL2022001477A1 (https=)
CR (1) CR20220318A (https=)
IL (1) IL293504A (https=)
MX (1) MX2022006877A (https=)
PE (1) PE20221169A1 (https=)
TW (1) TW202133847A (https=)
WO (1) WO2021113757A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511220B (zh) 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CA3151863C (en) * 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
WO2019217924A1 (en) * 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
CA3159436A1 (en) 2021-06-10
BR112022010733A2 (pt) 2022-08-23
TW202133847A (zh) 2021-09-16
WO2021113757A1 (en) 2021-06-10
CN114786658A (zh) 2022-07-22
JP2023504166A (ja) 2023-02-01
CR20220318A (es) 2022-10-07
AU2020397173A1 (en) 2022-06-23
MX2022006877A (es) 2022-07-11
IL293504A (en) 2022-08-01
PE20221169A1 (es) 2022-07-25
CL2022001477A1 (es) 2023-04-28
EP4069211A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
ES2303085T3 (es) Composiciones que afectan a la perdida de peso.
US20070099947A1 (en) Methods and compositions for the treatment of brain reward system disorders by combination therapy
US20030133951A1 (en) Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CN109562281B (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
US20240342156A1 (en) Methods for treating pain
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
JPH0157093B2 (https=)
JPS59501460A (ja) カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法
US20160074414A1 (en) Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
ES2968345T3 (es) Combinaciones de oxicodona y palmitoiletanolamina de N-aciletanolamina para reducir los efectos secundarios asociados a los opioides
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
KR20040020054A (ko) 통증 치료시 중독 예방
US8258185B2 (en) Use of neboglamine in the treatment of toxicodependency
JPH0232020A (ja) モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
EP0013110A1 (en) Analgesic composition
US20070244102A1 (en) Combination of Dermaciclane and Opoids as Analgesics
CA2919586A1 (en) A pharmaceutical composition, use of a pharmaceutical composition and method for treating the symptoms of excess alcohol consumption
HK40080562A (en) Use of a kv7 potassium channel opener for treating pain
US20070037835A1 (en) Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
JPH0259522A (ja) 悩代謝及び／又は精神症状改善剤
US20090281194A1 (en) Combinations for treating HIV-associated pain
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000